Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
01/2005
01/19/2005CN1565443A Daphnetin cyclodextrin clathrate compound, formulation and its preparation method
01/19/2005CN1565437A Verapamil hydrochloric acid drop pill and its preparation method
01/19/2005CN1565433A Hypocrellin water-soluble nanogranule and its uses
01/19/2005CN1565430A Allicin cyclodextrin clathrate compound, formulation and its preparation method
01/19/2005CN1565429A Instant oral film preparation and its preparation method
01/19/2005CN1565428A Chitosan microcapsule and its preparation method and uses
01/19/2005CN1565427A Gastric 5-fluorouracil double slow release tablet of float and stay type for curing gastric cancer
01/19/2005CN1565426A Formula containing water-soluble medicine slow release tablet and its preparation method
01/19/2005CN1565425A Rapid oral cavity disintegration tablet and its preparation method
01/19/2005CN1565420A Oral nano nourishing emulsion and its preparation method
01/19/2005CN1185257C Glucagon insulinotropic complexes, compositions and methods
01/19/2005CN1185253C Neoglycoproteins
01/19/2005CN1185014C Biodegradation type introducing agent of hardly water-soluble steroid, nonsteroid anti-inflammatory medicine, and its prepn. method
01/19/2005CN1185013C 赋形剂 Excipient
01/19/2005CN1185009C Eye preparation
01/19/2005CN1184971C Pharmaceutical combination preparations
01/19/2005CN1184962C Sertraline oral condensate
01/19/2005CN1184959C Compositions containing ascorbic acid and pectin
01/19/2005CN1184958C Erythropoietin Liposomal dispersion
01/19/2005CN1184903C Method for stabilizing liquid nutritional products and products so stabilized
01/18/2005US6844459 Pharmaceutical Composition
01/18/2005US6844364 Stabilization of retinoid compounds
01/18/2005US6844329 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin
01/18/2005US6844319 Targeting Hepatic Stellate Cells (HSC) involved in sclerotic and/or fibrotic diseases with carrier linked to amino acid sequence SRNLIDC
01/18/2005US6844318 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
01/18/2005US6844317 Methods for oxygen transport comprising a high oxygen affinity modified hemoglobin
01/18/2005US6844313 With protein or phosphoglyceride as aqueous solution; in vitro fertilization
01/18/2005US6844306 Water-soluble, chlorhexidine-containing compositions and use thereof
01/18/2005US6844172 Amylose products as matrix former for programmed release systems, process for preparing these amylose products, and process for making programmed release systems
01/18/2005US6844153 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
01/18/2005US6844009 Media in the form of complex dispersions, method for preparing same and uses
01/18/2005US6844008 Tablet composition
01/18/2005US6844004 Topical formulations of natamycin/pimaricin
01/18/2005US6844001 Adjuvants and copolymer compositions
01/18/2005US6843998 Methods and compositions for the treatment of pancreatitis
01/18/2005US6843980 Methods for using annexin for detecting cell death in vivo and treating associated conditions
01/18/2005US6843961 Deactivation pathogens; using riboflavin sensitizers; exposure to light source
01/16/2005CA2465681A1 The use of conjugated linoleic acid or derivative thereof for the treatment of the common cold
01/15/2005CA2464831A1 Stable non-dihydrate azithromycin oral suspensions
01/13/2005WO2005003775A2 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
01/13/2005WO2005003722A2 Nanotube structures having a surfactant bilayer inner wall coating
01/13/2005WO2005003296A2 Albumin fusion proteins
01/13/2005WO2005003295A2 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
01/13/2005WO2005003154A2 Compositions and methods for the diagnosis and treatment of tumor
01/13/2005WO2005003032A1 Zeolites for delivery of nitric oxide
01/13/2005WO2005002643A2 Method and products for delivering biological molecules to cells using multicomponent nanostructures
01/13/2005WO2005002627A2 Conjugated complement cascade inhibitors
01/13/2005WO2005002626A2 Therapeutic phosphonate compounds
01/13/2005WO2005002625A2 In-situ gelling drug delivery system
01/13/2005WO2005002615A1 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
01/13/2005WO2005002581A1 Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis
01/13/2005WO2005002554A2 A method of promoting sleep using topical administration of vasoactive agents
01/13/2005WO2005002548A1 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
01/13/2005WO2005002547A1 Matrix adjuvants and the drop pills prepared with them
01/13/2005WO2005002544A2 Stabilized particle dispersions containing nanoparticles
01/13/2005WO2005002516A2 Leukocyte internalized peptide-drug conjugates
01/13/2005WO2005002510A2 Deployable multifunctional hemostatic agent
01/13/2005WO2005002482A1 Transdermal hormone delivery system: compositions and methods
01/13/2005WO2004073654A3 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
01/13/2005WO2004069876A3 Trimeric polypeptide construct to induce an enduring t cell response
01/13/2005WO2004045633A3 Pharmaceutical composition comprising octreotide microparticles
01/13/2005WO2004006958A8 Stable pharmaceutical composition comprising erythropoietin
01/13/2005WO2003096983A3 Method of treating dyslipidemic disorders
01/13/2005WO2003017943A3 Therapeutic compositions and methods for treating viral infection
01/13/2005US20050010965 Method for producing tissue engineered meat for consumption
01/13/2005US20050010196 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
01/13/2005US20050010060 Novel quinones as disease therapies
01/13/2005US20050009988 Polymer derivatives having particular atom arrangements
01/13/2005US20050009931 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
01/13/2005US20050009918 Penetration enhancer; polysaccharide gum or polyacrylic acid thickener; aliphatic alcohol or ester or liquid polyol; water; and a buffer; relieves constriction of a blood vessel in vasospasm and restores blood flow; improving microcirculation in a replanted body part.
01/13/2005US20050009908 Aqueous dispersion comprising stable nonoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
01/13/2005US20050009857 Powder formulations containing tiotropium suitable for inhalation
01/13/2005US20050009800 Solid, free-flowing dry extract of a natural mixture of conjugated equine estrogens that has been applied by spraying an aqueous solution of the mixture onto a powdered or granular microcrystalline cellulose support that may contain lactose
01/13/2005US20050009791 Especially lysine, arginine, histidine, omithine and diaminobutyric acid; improved solubility for parenteral administration
01/13/2005US20050009783 Adjust solubility; dissolving taxol and cyclodextrin compound in ethanol; stirring; heating
01/13/2005US20050009741 Copolymer made by depolymerizing chitosan and acylating such as with glutaryl and propionyl groups; mixture with peptides such as buserelin, deslorelin, histrelin; ionic conjugate with parathyroid hormone
01/13/2005US20050009740 Mixture of carrier, target peptide and immune response triggers
01/13/2005US20050009739 Formulation strategies in stabilizing peptides in organic solvents and in dried states
01/13/2005US20050009738 Interleukin with nucleic acid carrier
01/13/2005US20050009735 Aqueous solution of insulin and surfactant; storage stability
01/13/2005US20050009730 Sleep disorders; side effect reduction
01/13/2005US20050009082 Beads, preparing method for the same, flow cytometer and program
01/13/2005US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases
01/13/2005US20050008746 Colorant for food and pharmaceuticals
01/13/2005US20050008707 Nanoparticulate megestrol formulations
01/13/2005US20050008706 Controlled agglomeration
01/13/2005US20050008698 Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose
01/13/2005US20050008697 Oral solid solution formulation of a poorly water-soluble active substance
01/13/2005US20050008696 Using compression, thermal cycle molding, and thermal setting molding modules in continuous process
01/13/2005US20050008694 Vaginally administratable progesterone-containing tablets and method for preparing same
01/13/2005US20050008692 Compositions comprising pectin and ascorbic acid
01/13/2005US20050008689 High efficiency encapsulation of charged therapeutic agents in lipid vesicles
01/13/2005US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems
01/13/2005US20050008679 synergistic efficacy; polar lipid supplement which contains antioxidants; soluble beta-glucan fiber; nutricine which enhances growth and/or strengthens the immune system; and a protein concentrate supplement such as whey protein concentrate
01/13/2005US20050008677 Mixture of carrageenan, plasticizer and active materials; film forming; pH controlling
01/13/2005US20050008650 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability
01/13/2005US20050008648 Mutant kinase; anticancer agents; supplying to leukemia blastocytes; antibody which detects cell surface antigen; antiproliferative agent
01/13/2005US20050008635 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
01/13/2005US20050008634 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
01/13/2005US20050008630 Preservation; nutrients; foods; using ascorbic and citric acid; oxidation resistance; by-product inhibition